Katherine Stueland, CHIEF EXECUTIVE OFFICER at GeneDx Holdings Corp. (WGS), sold 25,380 shares at $111.84 ($2.7M) on 2025-09-30, disclosed to the SEC on 2025-10-01.
Scheduled sale ($2.7M) by CHIEF EXECUTIVE OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.10 | 606 | $64K | 2.3% |
| 2 | $105.10 | 606 | $64K | 2.3% |
| 3 | $106.69 | 1,092 | $117K | 4.2% |
| 4 | $106.69 | 1,092 | $117K | 4.2% |
| 5 | $107.61 | 4,462 | $480K | 17.5% |
| 6 | $107.61 | 4,462 |
| $480K |
| 17.5% |
| 7 | $108.55 | 5,163 | $560K | 20.4% |
| 8 | $108.55 | 5,163 | $560K | 20.4% |
| 9 | $109.13 | 554 | $60K | 2.2% |
| 10 | $109.13 | 554 | $60K | 2.2% |
| 11 | $110.23 | 200 | $22K | 0.8% |
| 12 | $111.84 | 645 | $72K | 2.6% |
| 13 | $111.84 | 645 | $72K | 2.6% |
| 14 | $113.68 | 136 | $15K | 0.6% |
| Total | $108.13 avg | 25,380 | $2.7M | 100% |
| Filing → |
| WGS | SELL | 2026-06-18 | $638K | — | Filing → |
| WGS | SELL | 2026-06-11 | $196K | — | Filing → |
| WGS | SELL | 2026-05-01 | $142K | — | Filing → |